Annie Fourrier‐Réglat

4.9k total citations
125 papers, 3.7k citations indexed

About

Annie Fourrier‐Réglat is a scholar working on Toxicology, Oncology and Pharmacology. According to data from OpenAlex, Annie Fourrier‐Réglat has authored 125 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Toxicology, 26 papers in Oncology and 25 papers in Pharmacology. Recurrent topics in Annie Fourrier‐Réglat's work include Pharmacovigilance and Adverse Drug Reactions (37 papers), Pharmaceutical Practices and Patient Outcomes (20 papers) and Colorectal Cancer Treatments and Studies (19 papers). Annie Fourrier‐Réglat is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (37 papers), Pharmaceutical Practices and Patient Outcomes (20 papers) and Colorectal Cancer Treatments and Studies (19 papers). Annie Fourrier‐Réglat collaborates with scholars based in France, Italy and Netherlands. Annie Fourrier‐Réglat's co-authors include Nicholas Moore, Alexandre Pariente, Françoise Haramburu, Miriam Sturkenboom, Ghada Miremont‐Salamé, Mathiéu Molimard, Jean‐François Dartigues, Nuria Riera‐Guàrdia, Susana Perez‐Gutthann and Francesco Salvo and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Clinical Nutrition and Neurology.

In The Last Decade

Annie Fourrier‐Réglat

122 papers receiving 3.6k citations

Peers

Countries citing papers authored by Annie Fourrier‐Réglat

Since Specialization

Citations

This map shows the geographic impact of Annie Fourrier‐Réglat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Fourrier‐Réglat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Fourrier‐Réglat more than expected).

Fields of papers citing papers by Annie Fourrier‐Réglat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annie Fourrier‐Réglat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Fourrier‐Réglat. The network helps show where Annie Fourrier‐Réglat may publish in the future.

Co-authorship network of co-authors of Annie Fourrier‐Réglat

This figure shows the co-authorship network connecting the top 25 collaborators of Annie Fourrier‐Réglat. A scholar is included among the top collaborators of Annie Fourrier‐Réglat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Fourrier‐Réglat. Annie Fourrier‐Réglat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The value of a health insurance database to conduct pharmacoepidemiological studies in oncology 2019 ·Therapies ·(unknown), Charlotte Vaysse, Pauline Bosco‐Lévy, Pernelle Noïze, Annie Fourrier‐Réglat, Fabien Despas, Maryse Lapeyre‐Mestre	15
2	Prescription medicine use by pedestrians and the risk of injurious road traffic crashes: A case-crossover study 2017 ·PLoS Medicine ·(unknown), Marta Avalos, (unknown), Benjamin Contrand, Louis‐Rachid Salmi, Annie Fourrier‐Réglat, Blandine Gadegbeku, Emmanuel Lagarde, Ludivine Orriols	14
3	Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review 2017 ·Journal of Geriatric Oncology ·Amandine Gouverneur, Francesco Salvo, Driss Berdaï, Nicholas Moore, Annie Fourrier‐Réglat, Pernelle Noïze	30
4	Impact of a public media event on the use of statins in the French population 2016 ·Archives of cardiovascular diseases ·Julien Bezin, Florence Francis-Oliviero, (unknown), Philip Robinson, Patrick Blin, Annie Fourrier‐Réglat, Alexandre Pariente, Nicholas Moore	17
5	Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort 2016 ·Osteoporosis International ·Isabelle Carrière, (unknown), Joanna Norton, (unknown), Christophe Tzourio, Pernelle Noïze, Karine Pérès, Annie Fourrier‐Réglat, Marie‐Laure Ancelin	18
6	Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies 2014 ·Expert Opinion on Drug Safety ·Francesco Salvo, Stefania Antoniazzi, Mai Duong, Mathiéu Molimard, Fabienne Bazin, Annie Fourrier‐Réglat, Alexandre Pariente, Nicholas Moore	43
7	Continuation rates of levetiracetam in children from the EULEVp cohort study 2013 ·European Journal of Paediatric Neurology ·C. Dureau‐Pournin, Jean‐Michel Pedespan, C. Droz‐Perroteau, (unknown), Michael D. Mann, Clothilde Pollet, Philip Robinson, Jérémy Jové, Nicholas Moore, Annie Fourrier‐Réglat	4
8	Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study 2013 ·Leukemia & lymphoma ·Annie Fourrier‐Réglat, Pernelle Noïze, Thierry Façon, Jean‐Paul Fermand, Olivier Fitoussi, Gérald Marit, (unknown), Philip Robinson, (unknown), Jérémy Jové, R. Lassalle, (unknown), Angela Grelaud, Nicholas Moore, (unknown)	9
9	Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France 2013 ·European Journal of Clinical Pharmacology ·Julien Bezin, Alexandre Pariente, R. Lassalle, C. Dureau‐Pournin, Abdelilah Abouelfath, Philip Robinson, Nicholas Moore, C. Droz‐Perroteau, Annie Fourrier‐Réglat	35
10	the Eu-adr Alliance: A Federated Collaborative Framework for Drug Safety Studies : 667. 2012 ·Pharmacoepidemiology and Drug Safety ·Eva Molero, (unknown), Ferrán Sanz, José Luís Oliveira, Gianluca Trifirò, Annie Fourrier‐Réglat, Mariam Molokhia, Lars Pedersen, Scott Boyer, Lorenza Scotti, Rosa Gini, (unknown), Carlo Giaquinto, Marı́a Isabel Loza, Giampiero Mazzaglia, Johan van der Lei, Miriam Sturkenboom	1
11	Effect of Competition Bias in Safety Signal Generation 2012 ·Drug Safety ·Alexandre Pariente, Paul Avillach, Francesco Salvo, Frantz Thiessard, Ghada Miremont‐Salamé, Annie Fourrier‐Réglat, Françoise Haramburu, Bernard Bégaud, Nicholas Moore	59
12	The EU-ADR corpus: Annotated drugs, diseases, targets, and their relationships 2012 ·Journal of Biomedical Informatics ·Erik M. van Mulligen, Annie Fourrier‐Réglat, David Gurwitz, Mariam Molokhia, Ainhoa Nieto, Gianluca Trifirò, Jan A. Kors, Laura I. Furlong	92
13	Chemotherapy and targeted agents for colorectal cancer in a real‐life setting anticipate guidelines: the COLCHIC cohort study 2011 ·Fundamental and Clinical Pharmacology ·Denis Smith, Eric Terrebonne, (unknown), Jean‐Frédéric Blanc, Dominique Breilh, (unknown), (unknown), (unknown), R. Lassalle, Nicholas Moore, Annie Fourrier‐Réglat	4
14	Easily available adjustment criteria for the comparison of antibiotic consumption in a hospital setting: experience in France 2009 ·Clinical Microbiology and Infection ·Brice Amadéo, C. Dumartin, Peter Robinson, A.G. Venier, Pierre Parneix, J.P. Gachie, Annie Fourrier‐Réglat, A.M. Rogues	18
15	Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users 2009 ·British Journal of Clinical Pharmacology ·David Laharie, C. Droz‐Perroteau, Jacques Bénichou, M Amouretti, Patrick Blin, Bernard Bégaud, (unknown), (unknown), S. Lamarque, Yola Moride, F. Depont, Annie Fourrier‐Réglat, Nicholas Moore	22
16	Impact of Prescriber Nonresponse on Patient Representativeness 2008 ·Epidemiology ·Annie Fourrier‐Réglat, C. Droz‐Perroteau, Jacques Bénichou, F. Depont, M Amouretti, Bernard Bégaud, Yola Moride, Patrick Blin, Nicholas Moore	19
17	Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study 2008 ·American Journal of Clinical Nutrition ·Catherine Féart, Evelyne Peuchant, Luc Letenneur, Cécilia Samieri, (unknown), Annie Fourrier‐Réglat, Pascale Barberger‐Gateau	92
18	Modalités et évolution de la prescription d’olanzapine : résultats de l’étude de cohorte ECOL 2008 ·L Encéphale ·I. Gasquet, Philippe Flandre, (unknown), (unknown), (unknown), (unknown), Annie Fourrier‐Réglat	2
19	Agreement of expert judgment in causality assessment of adverse drug reactions 2005 ·European Journal of Clinical Pharmacology ·Yannick Arimone, Bernard Bégaud, Ghada Miremont‐Salamé, Annie Fourrier‐Réglat, Nicholas Moore, Mathiéu Molimard, Françoise Haramburu	77
20	Prescription du célécoxib (Célébrex®) lors de sa commercialisation : une étude conduite à partir de la base de données du régime général de l’assurance maladie de la région Aquitaine 2005 ·Therapies ·Annie Fourrier‐Réglat, (unknown), Mathiéu Molimard, Philippe Latry, Nicholas Moore, (unknown), Bernard Bégaud	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact